The oral, selective Janus kinase 1 inhibitor filgotinib confers a significant improvement in health-related quality of life in patients with active psoriatic arthritis (PsA), according to data from the phase II EQUATOR trial.
Exposure to psychotropic drugs and proton pump inhibitors (PPIs) contributes to an increase risk of clinical and nonvertebral fractures in postmenopausal women with severe osteoporosis, according to a study. Furthermore, teriparatide confers superior benefits for reducing the risk of fractures compared with risedronate, irrespective of such an exposure.
A programmed treatment strategy of refining infliximab (IFX) doses based on baseline serum tumour necrosis factor α falls flat in sustaining remission rate in rheumatoid arthritis patients after 1 year of IFX discontinuation, according to the results of the multicentre randomized RRRR* trial.
Treatment with lovastatin appears to have neither anti-inflammatory nor clinical effects on mild rheumatoid arthritis (RA) disease activity, although it produces a modest reduction in C-reactive protein (CRP) in patients not using biologics, according to the results of a phase II study.
There appears to be a borderline positive association between high-sensitivity C-reactive protein (hs-CRP) and long-term risk of coronary heart disease (CHD) among middle-aged and elderly individuals with hyperuricaemia, a study reports.
Monotherapy with tocilizumab (TCZ) shows good tolerability profile and results in remission in most patients with polymyalgia rheumatica (PMR) despite the absence of glucocorticoids, according to the 2-year results of a single-centre, open‐label pilot study.
Among patients with axial spondyloarthritis (axSpA) in Singapore, work productivity is lower in the presence of active disease, reduced physical function and poorer quality of life, as reported in a Singapore study.
Radiofrequency ablation and neuromodulation modalities for knee osteoarthritis (OA) potentially improve pain, functionality and disease-specific quality of life for up to 3–12 months with minimal localized complications, according to the results of a systematic review.
Exposure to corticosteroids in patients with autoimmune hepatitis (AIH) appears to contribute to increased risks of cataract, diabetes and bone fractures, a study has found. Notably, the fracture risk is elevated at low doses, while the risk of adverse events overall is dose-dependent and is reversible.
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Supplementation with oral nano vitamin D appears to moderate disease activity and severity grade of patients with active ulcerative colitis (UC), suggests a study, adding that this association is more evident in those achieving a target vitamin D level of 40 ng/mL.